The Company owns or exclusively licences a portfolio of specialist Intellectual Property (IP), which is used to formulate patent protected cosmeceutical, over the counter (OTC) and prescription-only products for branding and sale by pharmaceutical marketing companies.
The company’s technologies are suitable for New Chemical Entities (NCE), line extensions for existing patented actives, or the creation of super generics for existing drugs.
DDS is privately owned and was formed in 2005 by a management buyout from Disperse Group plc financed by Danish Private Equity. The main shareholder is MC2 Biotek aps.
